What is it about?
A multi-stakeholder collaboration between asthma centres and registries in Europe. The aim is to bring together different registries to enable large scale research of individuals with asthma in a real world setting. This will enable a better understanding of how asthma is managed and treated throughout Europe. A key feature of this collaboration is that it is patient stakeholder centered. It is focused on research that addresses problems patients care about most and the patient stakeholder perspective is well embedded. Patient stakeholders also form part of the leadership team.
Featured Image
Why is it important?
The care of severe asthma varies county by country and as we are now seeing new asthma therapies there is a need to understand how best to use those therapies in a real world setting. The SHARP collaboration will enable this and also help to drive the harmonisation of clinical management throughout Europe. The aim is for better care and an optimisation of management so that patients do not have to depend upon the use of oral steroids which have side effects.
Perspectives
From my perspective SHARP represents the power of what can be done when different stakeholders work well together to implement a bold vision. What is most important is that true dialogue is one of the key features of how the collaboration is working.
Scott Wagers
BioSci Consulting
Read the Original
This page is a summary of: The Severe Heterogeneous Asthma Research collaboration, Patient-centred (SHARP) ERS Clinical Research Collaboration: a new dawn in asthma research, European Respiratory Journal, November 2018, European Respiratory Society (ERS),
DOI: 10.1183/13993003.01671-2018.
You can read the full text:
Resources
Contributors
The following have contributed to this page
